Enfermedad neumocócica en la infancia

• Miguel Muñoz Sáez ^[1] ; Victor Manuel Navas López ^[1] ; J. A. Soult Rubio ^[1]
  1. [1] U. de Cuidados Intensivos Pediat., Hosp. Inf. Univ. Virgen del Rocio
• Localización: Pediátrika, ISSN 0211-3465, Vol. 23, Nº. 5, 2003, págs. 205-218
• Idioma: español
• Texto completo no disponible (Saber más ...)
• Resumen

  • Streptococcus pneumoniae was associated with numerous important infections in children, including respiratory infections and meningitis. Despite advances in therapeutics, high mortality rates remain associated with pneumococcal invasive diseases. The incidence of pneumococcal invasive diseases was increased in the last years. The past decade marked a global increase in penicillin and third-generation cephalosporins-resistant strains of Streptococcus pneumoniae. Combination therapy with cefotaxime plus vancomycin is currently recommended for the treatment of invasive diseases. The pneumococcal conjugate vaccine is protective against invasive pneumococcal infection. Therefore, all children aged < 2 years, children aged between 2-5 years with recurrent otitis media or attending on a day care center and all children with predisposing disease should receive the pneumococcal conjugate vaccine.